Evidence map›Paper›PMID 28831186›Full record

ReviewNature reviews. Gastroenterology & hepatology2017

The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.

Heitor S P de Souza, Claudio Fiocchi, Dimitrios Iliopoulos

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 234 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 7 pooled it
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04828031 phase1completednot on this mapstarted 2021, after this paper: background citation

Vitamin D Regulation of α4β7+ B Cell Immunophenotypes and Mucosal Antibody Response to Commensal Gut Bacteria in Patients With Inflammatory Bowel Disease

TypeinterventionalSponsorStanford UniversityRan2021 to 2023Enrolled48ConditionsInflammatory Bowel Diseases, Ulcerative Colitis, Crohn DiseaseArmsVitamin D
NCT05684484 phase4completednot on this mapstarted 2023, after this paper: background citation

Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis.

TypeinterventionalSponsorTanta UniversityRan2023 to 2024Enrolled52ConditionsUlcerative ColitisArmsRoflumilast 500 MCG Oral Tablet [DALIRESP], amino salicylic acid
3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 7 syntheses or guidelines pooled it, 436 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Prebiotics for induction and maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Risk Factors for Vitamin D Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Pooled it
  8. Trial
  9. Article
  10. Review
  11. The impact for causal associations between common diseases and inflammatory bowel disease: a disease-wide bidirectional Mendelian randomization study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  12. Article
  13. Berberine AlleviatesInternational journal of molecular sciences · 2026
    Article
  14. Article
  15. Journal of bacteriology · 2026
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Heitor S P de SouzaDepartment of Gastroenterology & Multidisciplinary Research Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
Claudio FiocchiDepartment of Pathobiology, Lerner Research Institute, Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Dimitrios IliopoulosCenter for Systems Biomedicine, Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
Cleveland Clinic Lerner College of Medicine · USUniversidade Federal do Rio de Janeiro · BRUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease and ulcerative colitis are prototypical complex diseases characterized by chronic and heterogeneous manifestations, induced by interacting environmental, genomic, microbial and immunological factors. These interactions result in an overwhelming complexity that cannot be tackled by studying the totality of each pathological component (an '-ome') in isolation without consideration of the interaction among all relevant -omes that yield an overall 'network effect'. The outcome of this effect is the 'IBD interactome', defined as a disease network in which dysregulation of individual -omes causes intestinal inflammation mediated by dysfunctional molecular modules. To define the IBD interactome, new concepts and tools are needed to implement a systems approach; an unbiased data-driven integration strategy that reveals key players of the system, pinpoints the central drivers of inflammation and enables development of targeted therapies. Powerful bioinformatics tools able to query and integrate multiple -omes are available, enabling the integration of genomic, epigenomic, transcriptomic, proteomic, metabolomic and microbiome information to build a comprehensive molecular map of IBD. This approach will enable identification of IBD molecular subtypes, correlations with clinical phenotypes and elucidation of the central hubs of the IBD interactome that will aid discovery of compounds that can specifically target the hubs that control the disease.

Indexed as

Drug DiscoveryEpigenomicsGastrointestinal AgentsGastrointestinal MicrobiomeGene-Environment InteractionGenetic Predisposition to DiseaseHumansInflammatory Bowel DiseasesProteomicsSystems BiologyTranscriptomeGastrointestinal Agents

Identifiers

PMID28831186
OpenAlexW2749616891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.